论文部分内容阅读
目的评价在新诊断胶质母细胞瘤患者中不同抗血管药物治疗何种效果最优。方法全面检索Pubmed、Cochrane library、Embase、CBM、CNKI、万方、维普各数据库,按照研究设计进行文献筛选和质量评估,提取数据后采用Stata13.0进行网状meta分析。结果分析揭示在新诊断胶质母细胞瘤患者中不同血管抑制剂加入/不加入标准替莫唑胺方案的治疗效果均优于其单一治疗方案;其中西仑吉肽2000mg/5/week干预效果最优,其次为贝伐单抗结合伊立替康治疗加入Stupp方案、贝伐单抗结合伊立替康方案、贝伐单抗结合Stupp方案、西仑吉肽2000mg/2/week方案。副作用方面揭示:仅西仑吉肽2000mg/2/week方案和BEV方案比Stupp方案的副作用发生率高,差异有统计学意义(P<0.05);其他方案与Stupp方案相比副作用发生率均无统计学差异(P>0.05)。结论在符合本研究标准的新诊断胶质母细胞瘤患者中不同血管抑制剂的干预效果均优于Stupp方案;然而,当前研究的样本量相对较少,贝伐单抗相关的治疗方案和西仑吉肽相关的治疗方案何种效果更优并不能给予确定的结论。
Objective To evaluate the optimal effect of different anti-angiogenic drugs in newly diagnosed glioblastoma patients. Methods The databases of Pubmed, Cochrane library, Embase, CBM, CNKI, Wanfang and VIP were searched comprehensively, and the literatures were screened and evaluated according to the research design. The data were extracted and the net meta-analysis was performed using Stata13.0. Results analysis revealed that the addition of different antihypertensive agents to the newly diagnosed glioblastoma patients was superior to the single treatment regimen with and without the standard temozolomide regimen; the intervention with cilengitide at 2000mg / 5 / week was the best, Followed by bevacizumab plus irinotecan treatment with Stupp, bevacizumab with irinotecan, bevacizumab with Stupp, cilengitide 2000mg / 2 / week. Side effects revealed: only Cilengitide 2000mg / 2 / week program and BEV program than the side effects of Stupp program incidence, the difference was statistically significant (P <0.05); other programs compared with Stupp side effects were no Statistical difference (P> 0.05). Conclusions Interventions with different antihypertensive agents were superior to those of Stupp in newly diagnosed glioblastoma patients that met the criteria of this study; however, the current study has relatively small sample sizes and bevacizumab-related regimens and western Which of the treatment regimens associated with londigenin is more effective does not give definitive conclusions.